Annual Report 2015
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2015 now is available at the company’s website: www.medivir.com.- Medivir continued to build long-term value in 2015 via a R&D portfolio based on our established and proven technology platform. One of the most important of these steps was the completion, according to plan, of safety testing in our MIV-711 osteoarthritis project, followed, at the end of the year, by the approval to start a phase II trial on osteoarthritis patients. We have a good starting point, with highly competent employees